Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 randomized double-blind placebo-controlled dose-ranging study of oral NS-863 in pulmonary arterial hypertension
MOH_2026-09-22_017044Phase 2Not yet recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of NS-863 in pulmonary arterial hypertension (PAH) (3 arms), sponsored by NS Pharma, Inc. Primary endpoints: Efficacy and safety of NS-863 and Change in pulmonary blood flow/hemodynamics. Planned start Jul 2026; status: not yet recruiting.
02
Drugs
NS-863
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2026-09-22_017044.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2026-09-22_017044.